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Plasma lipoproteins are important determinants of ath-
erosclerosis, a disease of the large arteries that underlies
most deaths in industrialized nations (Lusis 2000). Ath-
erogenesis begins in response to an arterial injury, which
leads to a series of inflammatory, proliferative, and apop-
totic cellular events that produce complicated arterial-
wall plaques (Ross 1993, 1999). Some plaques are vul-
nerable to rupture and thrombosis, leading to arterial
occlusion, whose location specifies the clinical presen-
tation, usually a heart attack or stroke (Ross 1993,
1999). Genetic susceptibility plays a key role in ather-
osclerosis, particularly when clinical end points strike
early in life. Some risk factors—such as dyslipidemia,
diabetes and hypertension—themselves have complex
genetic determinants. Other risk factors—such as smok-
ing, poor diet, inactivity, and stress—can modulate ex-
pression of the genetic susceptibility.
Study of monogenic dyslipidemias has exposed key
metabolic mechanisms. The exemplar was the autosomal
dominant (AD) form of familial hypercholesterolemia
(FH) (MIM 143890), whose characterization led to the
discovery of receptor-mediated endocytosis (RME) via
the LDL receptor (Brown and Goldstein 1986). This in
turn led to development of statin drugs, which reduce
LDL cholesterol and coronary heart disease (CHD)mor-
tality (4S Investigators 1994) and which are now used
by tens of millions of people. However, LDL-cholesterol
reduction does not always prevent CHD (Superko
1996), and many patients with CHD do not have ele-
vated LDL cholesterol as their primary dyslipidemia (Ge-
nest et al. 1992). Recent delineation of the molecular
basis of other monogenic dyslipidemias therefore has the
potential to reveal new pathways that could lead to ad-
ditional downstream public-health benefits for CHD
reduction.
Nongenetic and nonhuman experiments have revealed
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many fascinating gene products for lipoprotein metab-
olism. This review will focus on monogenic lipoprotein
disorders, summarized in table 1. Before 1999, most
mutations for monogenic lipoprotein disorders were
identified on the basis of the function of the gene prod-
uct. Since 1999, positional cloning has revealed novel
genes—such as those for Tangier disease, sitosterolemia,
and autosomal recessive (AR) hypercholesterolemia
(ARH). Rather than describing in depth any particular
pathway, this review will attempt to position newer ge-
netic findings within the context of prior knowledge of
plasma lipoprotein metabolism.
Plasma Lipids and Lipoproteins
The most clinically relevant plasma lipids are cholesterol
and triglyceride (TG). Cholesterol in particular has cap-
tivated generations of researchers: cholesterol-related
discoveries serve as scientific milestones for the 20th cen-
tury (Vance and van den Bosch 2000). Cholesterol is a
structural component of cell membranes and is the pre-
cursor of steroid hormones and vitamin D and also of
oxysterols and bile acids (BA), which activate nuclear-
hormone receptors involved in sterol metabolism (Rus-
sell 1999). Cholesterol is also required for activation of
sonic hedgehog, which is involved with forebrain pat-
terning (Parisi and Lin 1998). But cholesterol also has
a dark side. For instance, cholesterol entrapped within
arterial-wall macrophages leads to foam-cell formation
and plaque growth. In men, a rise in total plasma cho-
lesterol from 5.2 to 6.2 mmol/liter (from 200 to 240
mg/dl) is associated with a threefold-increased risk of
death from CHD (Stamler et al. 2000).
Lipoproteins are spherical macromolecules that trans-
port cholesterol and TG—in addition to phospholipid
(PL), fat-soluble antioxidants and vitamins, and cho-
lesteryl ester (CE)—through plasma, from sites of syn-
thesis and absorption to sites of uptake. Lipoproteins
have a nonpolar lipid core with a hydrophilic surface
coat containing free cholesterol (FC), PL, and apoli-
poprotein (apo) molecules. The main TG-carrying lip-
oproteins are chylomicrons (CM) and very-low-density
lipoprotein (VLDL). The main cholesterol-carrying lip-
oproteins are LDL and HDL. Lipoproteins are distin-
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Table 1
Monogenic Disorders Affecting Plasma Lipoproteins
Lipoprotein Profile and Gene Gene Product Disease(s)
Cholesterol:
LDL:
Increased:
LDLR (MIM 143890) LDL receptor AD FH
APOB (MIM 107730) apo B FDB
ARH (MIM 603813) ARH AR FH
LIPA (MIM 278000) Lysosomal lipase Wolman disease, cholesteryl-ester–storage disease
Decreased:
MTP (MIM 157147) MTP ABL
APOB (MIM 107730) apo B Hypobetalipoproteinemia
SLC10A2 (MIM 601295) ASBT Primary BA malabsorption
HDL:
Decreased:
APOA1 (MIM 107680) apo AI Analphalipoproteinemia
LCAT (MIM 245900) LCAT Fish-eye disease, familial LCAT deficiency
ABCA1 (MIM 600046) ABCA1 Tangier disease, familial hypoalphalipoproteinemia
Increased:
CETP (MIM 118470) Cholesteryl-ester–transfer protein CETP deficiency
LIPC (MIM 151670) HL HL deficiency
Triglycerides:
APOC2 (MIM 207750) APOC2 APOC2 deficiency, hyperchylomicronemia
LPL (MIM 238600) LPL LPL deficiency, hyperchylomicronemia
Remnants and IDL:
APOE (MIM 107741) apo E Dysbetalipoproteinemia
LIPC (MIM 151670) HL HL deficiency
Sitosterol:
ABCG5 (MIM 605459) ATP-binding cassette, subfamily G, member 5 Sitosterolemia
ABCG8 (MIM 605460) ATP-binding cassette, subfamily G, member 8 Sitosterolemia
guished from each other on the basis of size, density,
electrophoretic mobility, lipid and protein content, com-
position, and function (table 2). Lipoprotein metabo-
lism is a complex network of biochemical processes,
including assembly, secretion, processing, and catabo-
lism, as shown in figure 1. The liver (fig. 1A), intestine
(fig. 1B), and peripheral cells (fig. 1D) are important
determinants of plasma lipoproteins (fig. 1C).
A Bird’s-Eye View of Lipoprotein Metabolism
The Liver
In the liver (and also in extrahepatic tissues), FC (fig.
1A) is synthesized from acetyl coenzyme A (CoA) (fig.
1A, Ac) by a multistep synthetic pathway, with the last
committed step catalyzed by 3-hydroxy-3-methylglutaryl
(HMG) CoA reductase. FC can also be (re-)esterified to
CE (fig. 1A) by an acyl CoA:cholesterol acyltransferase
(ACAT), also called “sterol O-acyltransferase” (SOAT2)
(fig. 1A), for incorporation into cytosolic lipid-storage
droplets or lipoprotein assembly. Lipoprotein-derived CE
can be hydrolyzed to release FC by lysosomal CE hydro-
lase (CEH) (fig. 1A), also called “lysosomal acid lipase,”
and a distinct neutral CEH hydrolyzes cytoplasmic CE.
Hepatic FC can be diverted to BA (fig. 1A) synthetic path-
way by hydroxylation, for which cholesterol 7-a-hydrox-
ylase (CYP7A1) (MIM 118445) (fig. 1A) is rate limiting.
Fat or carbohydrate not required by the liver for energy
or synthesis is converted to TG (fig. 1A) by several bio-
synthetic pathways. The microsomal TG-transfer protein
(MTP) (fig. 1A) in hepatocytes directs assembly of CE
and TG together with apo B-100 and apo E, to produce
VLDL (fig. 1C and table 2) for secretion into plasma.
The Intestine
In the intestine, dietary fat is processed prior to ab-
sorption; for instance, pancreatic lipase (PNLIP) (MIM
246600) (fig. 1B) hydrolyzes dietary TG to liberate free
fatty acid (FFA) (fig. 1B), which is absorbed both passively
and actively. BA (fig. 1A) from liver is secreted and sub-
sequently reabsorbed through specific mediators. BA per-
mits absorption of lumenal FC (fig. 1B). The ABCG5 and
ABCG8 half-transporters (fig. 1B) may also re-excrete ab-
sorbed FC, in addition to plant sterols such as sitosterol
(fig. 1B, S). Intestinal ABCA1 (fig. 1B) also mediates re-
excretion of absorbed FC into the bowel lumen. There is
likely to be redundancy between the ABCA1, ABCG5,
and ABCG8 pathways for intestinal FC absorption.
Within enterocytes, processing by SOAT2 (fig. 1B) and
TG biosynthetic pathways prepare CE and TG, respec-
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Table 2
Features of Primary Plasma Lipoproteins
LIPOPROTEIN
CLASS
SIZE
(nm)
DENSITY
(g/ml)
ELECTROPHORETIC
MOBILITY
TG
(% wt)
PL
(% wt)
CHOLESTEROL
(% wt)
PROTEIN
(% wt)
PRIMARY
APOLIPOPROTEIN(S)Free Esterified
CM 75–1,200 .94 Origin (cathode) 80–95 3–6 1–3 2–4 1–2 A-I, A-IV, B-48, C-I, C-III, E
VLDL 30–70 .94–1.006 Pre-b 45–65 15–20 4–8 16–22 6–10 B-100, E, C-I, C-II, C-III
LDL 18–30 1.019–1.063 b 4–8 18–24 6–8 45–50 18–22 B-100
HDL 5–12 1.063–1.21 a 2–7 26–32 3–5 15–20 45–55 A-I, A-II, E
tively, for MTP-mediated assembly (fig. 1B) with apo B-
48 and apo E into CM (fig. 1C), which is the main li-
poprotein carrying fat of exogenous origin secreted into
lymph and plasma.
Plasma
Within the capillaries of adipose tissue and muscle,
CM and VLDL core TG are hydrolyzed to FFA by en-
dothelial-bound lipoprotein lipase (LPL) (fig. 1C), which
uses apo CII (APOC2) (fig. 1C) as a cofactor. FFAs are
either re-esterified and stored as TG in fat cells or oxi-
dized to provide energy in muscle. CM and VLDL are
remodeled into the short-lived, smaller, denser, more CE-
rich CM remnants (CMR) (fig. 1C) and intermediate-
density lipoprotein (IDL) (fig. 1C), respectively. CMR
and some IDL are cleared by apo E-mediated endocytosis
through hepatic-remnant receptors (fig. 1A), contribut-
ing to the hepatic CE pool (fig. 1A). IDL that is not
cleared is then hydrolyzed by hepatic lipase (HL) (fig.
1C, LIPC), making smaller, CE-rich LDL particles (fig.
1C).
Approximately 70% of total plasma cholesterol is par-
titioned into LDL (fig. 1C). LDL is actually a spectrum
of particles whose main lipid is CE and whose defining
protein moiety is a single molecule of apo B-100 (table
2). LDL is principally responsible for cholesterol trans-
port into peripheral tissues. LDL has a plasma half-life
of ∼3 d and is cleared by the binding of apo B-100 to
hepatocyte LDLR (fig. 1A), clustering in coated pits,
internalization by RME, and degradation in lysosomes.
The ARH product (fig. 1A) probably interacts with the
LDLR. After RME, apo B-100–containing lipoproteins
are processed through lysosomes, and freed cholesterol
enters the cellular pool. As hepatic FC increases, LDLR
transcription is suppressed, RME is reduced, and plasma
LDL rises. Chronic excess LDL alters arterial endothelial
function. LDL that does not undergo regulated RME is
taken up in an unregulated manner by scavenger recep-
tors (such as CD36 and SRA-I/II; not shown in fig. 1)
on arterial-wall macrophages. Entrapped LDL lipids can
become oxidized, generating toxic intermediates that in-
duce cytokine production and chemotaxis of inflam-
matory cells (Ross 1999). Arterial-wall macrophages can
become engorged with cholesterol from LDL, creating
foam cells, which are a key component of atherogenic
plaques (Ross 1993).
Apolipoproteins provide plasma lipoproteins with
structural stability and solubility. They also serve as li-
gands for receptors and/or as activators for enzymes.
Apo B-100 of VLDL, IDL, and LDL (fig. 1C) is synthe-
sized in the liver, whereas apo B-48 of CM and CMR
(fig. 1C) is synthesized in the small intestine. Both apo
B-100 (4,356 amino acids) and apo B-48 (2,152 amino
acids) are APOB (MIM 107730) products. Apo B-48
mRNA is produced by editing of the apo B-100 mRNA
(Hodges and Scott 1992), mediated by a 27-kD editase
(APOBEC1) (MIM 600130). Other apolipoproteins
represented in figure 1C are APOC2 (a cofactor for LPL),
apo E (a ligand for RME), and apo AI (an activator of
LCAT).
“Reverse Cholesterol Transport” (RCT)
RCT describes cholesterol transport from peripheral
cells back to the liver, for secretion in bile (Glomset
1980). The liver and small intestine produce nascent
HDL particles (fig. 1C), which attract excess FC both
from extrahepatic cells and from other circulating lip-
oproteins. Within peripheral cells, SOAT1 and CEH (fig.
1D) maintain the balance between FC and CE. PL (fig.
1D) and FC (fig. 1D) that accumulate in the intimal layer
of the arteries are transferred to apo AI (fig. 1C) of
nascent HDL, a process mediated by the ABCA1 (fig.
1D). Using apo AI as a cofactor, plasma lecithin:cho-
lesterol acyltransferase (LCAT) (fig. 1C) converts FC to
CE, providing a source of core lipid and thus supporting
plasma HDL levels. Plasma CE-transfer protein (CETP)
(fig. 1C) and PL-transfer protein (PLTP) (MIM 172425)
(fig. 1C) modify HDL by shuttling CE and PL between
HDL and TG-rich lipoproteins (fig. 1C,VLDL and CM),
and these lipoproteins are rapidly cleared by the liver,
as described above. HL (encoded by LIPC, as shown in
fig. 1D) hydrolyzes HDL TG, thus reducing HDL size.
HDL delivers cholesterol to the liver, and scavenger-re-
ceptor BI (fig. 1A, SRBI) mediates selective uptake of
lipids. Macrophages ingest large amounts of lipoprotein-
derived cholesterol and cannot down-regulate uptake in
1164 Am. J. Hum. Genet. 69:1161–1177, 2001
Figure 1 Four compartments important in plasma lipoprotein metabolism: liver (A), intestine (B), plasma (C), and peripheral cell (D).
The main plasma lipoproteins—namely, CM (and its remnant, CMR), VLDL (and its remnant, IDL), LDL, and HDL—are represented as spheres
within the shaded plasma compartment (C). Incoming arrows to the plasma compartment represent secretion from tissues into plasma, and
outgoing arrows from the plasma represent uptake into tissues. Within the plasma space, arrows between lipoproteins represent processing
reactions. In the liver (A) and peripheral cell (D), arrows between lipid constituents—such as the cellular pools of FC, CE, TG, acetyl coenzyme
A (Ac), BA, and PL—indicate intracellular processes. In the intestinal lumen (B), arrows between lipids indicate processing and/or progress
through the intestinal tract. In the intestine (B), outgoing and incoming arrows involving enterocytes indicate, respectively, secretion into and
absorption from the lumen of lipids (B), including FFA, TG, FC, BA, and sitosterol (S). Gene products are shown, throughout the figure, in a
lighter font. Gene products involved in lipoprotein secretion and catabolism, in intracellular lipid processing, and in intestinal lipid transport
are shown beside the appropriate arrow. Intestinal intracellular ABCG5 and ABCG8 are indicated (B). Apolipoproteins are shown on the
surfaces of the plasma lipoproteins (C). Abbreviations are defined in table 1 and in the text. Earlier studies of the molecular basis of monogenic
dyslipidemias—such as mutant LDLR in AD FH, mutant genes resulting in abnormal apolipoproteins (APOB, APOE, APOC2, and APOAI),
plasma enzyme deficiencies (LPL, LIPC, CETP, and LCAT), and ABL (MTP)—provided key insights into plasma lipoprotein metabolism. The
recent positional cloning–based discoveries of genes for three other monogenic dyslipidemias—ARH in AR FH (A), ABCG5 and ABCG8 in
sitosterolemia (B), and ABCA1 in Tangier disease (B and D)—have added new routes to the lipoprotein metabolic road map.
response to cholesterol loading (Brown and Goldstein
1983). Macrophage receptors for oxidized LDL (such as
CD36 and SR-AI/II; not shown in fig. 1) can be regu-
lated, but not by cholesterol (Nicholson et al. 2000; van
Berkel et al. 2000). Consequently, to prevent lipid ac-
cumulation, macrophages depend on cholesterol efflux
through transfer to HDL. HDL particles can be defined
on the basis of either size (table 2) or protein compo-
sition (Leroy et al. 1993). In addition to RCT, HDL
might (1) suppress cytokine-induced adhesion of endo-
thelial cells, (2) protect LDL from oxidation, and/or (3)
have anticoagulant effects (Lusis 2000; Tall and Wang
2000).
Plasma Lipoproteins and Risk of CHD
An enormous body of literature indicates that risk of
CHD is directly related to plasma total- and LDL-cho-
lesterol concentration (Stamler et al. 2000) and inversely
related to plasmaHDL-cholesterol concentration(Rhoads
et al. 1976; Stamler et al. 2000). HDL cholesterol !0.9
mmol/liter (!35 mg/dl) is an independent risk factor for
CHD: low HDL is the most common dyslipidemia in
patients with CHD who are age !60 years (Genest et al.
1992). Plasma LDL-cholesterol and apo-B concentration
are correlated (Sniderman 1988), as are plasma HDL-
cholesterol and apo-AI concentration (Moll et al. 1989).
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The relationship between plasma TG and CHD is more
difficult to prove, since elevated plasma TG is often ac-
companied by low HDL cholesterol. However, elevated
plasma TG, usually due to excess VLDL and/or remnant
particles, appears to be independently associated with in-
creased risk of CHD (Austin 1999; Yarnell et al. 2001),
especially in familial hypertriglyceridemia (Austin et al.
2000). Grossly elevated plasma TG, due to excess CM,
is associated with increased risk of pancreatitis (Santa-
marina-Fojo 1998).
Disorders Affecting Plasma LDL
Monogenic Disorders with LDL Excess
The archetypal monogenic disorder of LDL excess is
AD FH, which results from one of 1600 reported LDLR
mutations that reduce LDLR number and/or activity (see
The Low Density Lipoprotein Receptor (LDLR) Gene in
Familial Hypercholesterolemia web site). In most popu-
lations, FH heterozygotes and homozygotes have fre-
quencies of ∼1:500 and ∼1:106, respectively, with higher
frequencies in some ethnic groups, due to founder effects.
Because of the gene-dosage relationship with phenotypic
severity, FH can also be considered as an autosomal co-
dominant disorder. FH homozygotes have up to eightfold-
increased plasma LDL, with prominent tissue deposits of
cholesterol (xanthomata), and CHD as early as child-
hood. FH heterozygotes have approximately threefold-
increased plasma LDL, with xanthomata, and greatly in-
creased risk of CHD in mid adulthood (Simon Broome
Register Group 1991). DNA analysis may complement
clinical and biochemical diagnosis of FH (Williams et al.
1993). Environment (Williams et al. 1986; Sijbrands et
al. 2001) and other genes (Emi et al. 1991) can modulate
the clinical severity of FH.
A second monogenic AD disorder causing elevated
LDL cholesterol, called “familial defective apo B-100”
(FDB), results from missense mutations in APOB that
affect binding to LDLR (Myant 1993). In Europeans,
heterozygous FDB has a prevalence of ∼1:1,000 and is
clinically milder than heterozygous FH (Myant 1993).
A third monogenic disorder causing elevated LDL cho-
lesterol, ARH, has been characterized recently (Garcia et
al. 2001). ARH is distinct from homozygous FH, because
parents have normal plasma LDL cholesterol, unlike the
parents of FH homozygotes, who have elevated LDL.
Children and adolescents with ARH have severe hyper-
cholesterolemia, with skin findings and early CHD. ARH
was initially mapped to chromosome 1p35 (Zuliani et al.
1995, 1999). Mutant ARH (MIM 605747) encodes a
putative adapter protein, which might facilitate LDLR
movement into coated pits (fig. 1A) (Goldstein andBrown
2001). Interestingly, mutant ARH was found in one fam-
ily in which a locus on 15q25-q26 previously had been
demonstrated (Ciccarese et al. 2000).
Additional genetic heterogeneity for elevated LDL cho-
lesterol has been suggested by reports of a new locus for
AD FH (Haddad et al. 1999; Hunt et al. 2000). Also,
sequencing of LDLR in 60 subjects with clinical AD FH
has indicated that ∼40% had neither an LDLRmutation
nor an FDB mutation (Wang et al. 2001), a finding con-
sistent with genetic heterogeneity. Finally, mutant LIPA
encoding lysosomal cholesterol hydrolase (lysosomal acid
lipase) underlies both Wolman disease (MIM 278000)
and the milder CE-storage disease (CESD) (Anderson et
al. 1994), both ofwhich have elevated plasmaLDL,which
is also consistent with genetic heterogeneity for the ele-
vated-LDL-cholesterol phenotype.
Monogenic Disorders with LDL Deficiency
The archetypal disorder of LDL deficiency is abeta-
lipoproteinemia (ABL) (MIM 200100), a very rare (fre-
quency ∼1:106) AR disease defined by the absence of
apo B-100–containing lipoproteins, giving very low
plasma cholesterol and TG (Rader and Brewer 1993).
ABL was described in patients with acanthocytosis, spi-
nocerebellar degeneration, and atypical retinitis pigmen-
tosa (Bassen and Kornzweig 1950). Mutations in MTP
(MIM 157147) cause ABL (Wetterau et al. 1992; Narcis
et al. 1995). MTP in the liver (fig. 1A) and intestine (fig.
1B) is required for assembly and secretion of apo
B–containing lipoproteins (Wetterau et al. 1991). MTP
is a heterodimer composed of the multifunctional en-
zyme protein disulfide isomerase (PDI) and a 97-kD sub-
unit. PDI appears necessary to maintain the structural
integrity of MTP; however, no mutations in PDI have
been reported.
Homozygous familial hypobetalipoproteinemia (FHBL1)
(MIM 107730) is another AR disorder of LDL deficiency,
and it is caused byAPOBmutations affecting the integrity
of the LDL particle (Schonfeld 1995). FHBL1 is distinct
from ABL because parents have half-normal plasma apo
B-100 and LDL cholesterol, unlike the parents of ABL
homozygotes, who have no lipoprotein abnormalities. In
both ABL and FHBL1, subjects develop fatmalabsorption
and fat-soluble vitamin deficiencies. High oral doses of
fat-soluble vitamins can arrest the neuropathy and reti-
nopathy (Muller et al. 1985). Interestingly, heterozygosity
for both mutant APOB, causing FHBL1, and mutant
LDLR, causing FH, was associated with normal plasma
lipoproteins (Emi et al. 1991).
Additional genetic heterogeneity for low LDL choles-
terol was suggested earlier (Hobbs et al. 1989), and a
new locus for AD hypobetalipoproteinemia recently has
been reported (Knoblauch et al. 2000). Also,APOBmu-
tations account for a minority of cases of hypobetali-
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poproteinemia (Wu et al. 1999), a finding consistent
with additional genetic heterogeneity. Compound het-
erozygosity for mutations in the apical sodium-depen-
dent BA transporter (ASBT), encoded by SLC10A2
(MIM 601295), in a patient with steatorrhea, growth
retardation, increased BA output, and low plasma LDL
cholesterol (Oelkers et al. 1997) further illustrated the
genetic heterogeneity of low LDL. Defining the mutation
in another rare disorder, called “Anderson disease,”
which is characterized by the absence of apo B-48–con-
taining lipoproteins, might reveal a new metabolic path-
way, since MTP and apolipoprotein genes are normal
(Dannoura et al. 1999).
Disorders Affecting Plasma HDL
Monogenic Disorders with HDL Deficiency
Several monogenic disorders are characterized by
HDL deficiency, which is also called “hypoalphalipo-
proteinemia.” The first molecular defects causing low
HDL were discovered by sequence analysis of candidate
genes in HDL metabolism; for instance, homozygosity
for some mutations in APOA1 (MIM 107680) affects
the assembly of HDL and has been found in patients
with very low HDL cholesterol, xanthomas, and early
CHD (Dammerman and Breslow 1995), and homozy-
gosity for mutant LCAT (MIM 245900) results in im-
paired esterification of FE and produces many lipopro-
tein abnormalities, including markedly depressed HDL
cholesterol, abnormal lipid deposition in tissues, anemia,
renal disease, and early CHD (Kuivenhoven et al.
1997)—and certain LCATmutations cause “fish-eye dis-
ease” (MIM 136120), which is associated with lowHDL
and profound corneal deposits but not with other at-
tributes of LCAT deficiency (Kuivenhoven et al. 1997).
In 1999, three groups independently used positional
cloning to show that mutant ABCA1 (MIM 600046)
encoding the ABCA1 transporter was the basis of Tan-
gier disease (TD) (Bodzioch et al. 1999; Brooks-Wilson
et al. 1999; Rust et al. 1999), an extremely rare AR
disease. The TD index cases had orange tonsils and un-
detectable HDL cholesterol (Fredrickson et al. 1961).
Other findings have included hepatosplenomegaly, pe-
ripheral neuropathy, altered plasma apo B–containing
lipoproteins (Herbert et al. 1978), and impaired in vitro
efflux of cholesterol and PL from fibroblasts (Francis et
al. 1995). Plasma HDL cholesterol is also decreased in
TD heterozygotes, and risk of CHD is increased in TD
homozygotes and heterozygotes (Schaefer et al. 1980;
Serfaty-Lacrosniere et al. 1994; Clee et al. 2000).
ABCA1 had earlier been implicated in foam-cell me-
tabolism (Langmann et al. 1999), with increased gene
expression mediated by binding of oxysterol-activated
nuclear-hormone receptors (Costet et al. 2000). ABCA1
is part of a superfamily of ∼50 transmembrane proteins
that couple ATP hydrolysis to substrate transport
(Schmitz et al. 2000). Mutations in ABC transporters
underlie various diseases (Schmitz et al. 2000). TD mu-
tations probably impair the ability of cell-surface
ABCA1 transporters to transfer cholesterol to HDL (fig.
1D) (Lawn et al. 1999), and the lipid-poor HDL are
more prone to catabolism. ABCA1 is also important in
regulation of intestinal cholesterol absorption (fig. 1B)
(Repa et al. 2000).
Additional genetic heterogeneity for low HDL cho-
lesterol has been suggested by genomewide scanning
(Kort et al. 2000). Also, mutations in ABCA1 and in
other candidate genes account for low HDL in a mi-
nority of subjects (Brooks-Wilson et al. 1999), a finding
consistent with genetic heterogeneity. Glucocerebrosi-
dase mutations in Gaucher disease type 1 (GD1) (MIM
230800) are associated with low HDL (Pocovi et al.
1998). Finally, a subtype of Niemann-Pick disease is as-
sociated with very low HDL (Viana et al. 1990), rein-
forcing the importance that the Niemann-Pick type C
protein (NPC1) (MIM 257220) has for intracellular cho-
lesterol transport (Dietschy and Turley 2001).
Monogenic Disorders with HDL Excess
Rare deficiencies of two processing proteins—namely,
HL and CETP—have been associated with increased
plasma HDL cholesterol. In HL deficiency (MIM
151670), compound heterozygosity for mutant LIPC
resulted in elevated plasma IDL, HDL, and apo AI;
in TG enrichment of LDL and HDL; abnormal ca-
tabolism of remnant lipoproteins; failure to remodel
HDL; and early CHD (Hegele et al. 1993). In CETP
deficiency (MIM 118470), homozygosity or com-
pound heterozygosity for CETP mutations resulted in
elevated plasma HDL and apo AI, with reduced LDL
and apo B. The relationship between mutant CETP
and CHD is unclear (Zhong et al. 1996; Tall et al.
2000). CETP mutations are a common cause of high
HDL in Japanese individuals (Inazu et al. 1990), but
the molecular basis for elevated HDL in most other
populations is unknown.
Disorders Affecting TG
Complete LPL deficiency is an extremely rare (frequen-
cy ∼1:106) AR disease resulting from homozygosity
or compound heterozygosity for mutant LPL (MIM
238600) (Santamarina-Fojo 1998; Talmud 2001). More
than 60 LPL mutations have been identified (Santamar-
ina-Fojo 1998). Four subjects with chylomicronemia and
CHD (Benlian et al. 1996) were the exception that
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proved the clinical rule that CM themselves do not cause
CHD. Chylomicronemia also results from deficiency of
the cofactor APOC2 (fig. 1C), owing to rare loss-of-
function mutations in APOC2 (MIM 207750), which
provided the first demonstration that a mutant apoli-
poprotein causes dyslipidemia (Breckenridge et al. 1978;
Cox et al. 1978).
Familial Combined Hyperlipidemia (FHCL)
FHCL (Fredrickson type IIB) (MIM 144250), charac-
terized by elevations (190th percentile) of both plasma
total cholesterol and TG in probands and affected rel-
atives, may be the most common genetic dyslipidemia
causing CHD (Goldstein et al. 1973; Nikkila and Aro
1973; Rose et al. 1973). Initially considered to have an
AD pattern of transmission, FCHL was subsequently
shown to have more-complex inheritance (Iselius 1981;
Williams and Lalouel 1982; Cullen et al. 1994). This
variability of the lipid phenotype among and within af-
fected subjects is a formidable impediment to identifi-
cation of genetic determinants. Also, the intermediate
phenotypes in FCHL are heterogeneous. Although the
core metabolic defect in FCHL is overproduction of apo
B-100 (Kissebah et al. 1981; Cortner et al. 1991), there
are several other metabolic defects (Cabezas et al. 1993;
Cianflone et al. 1995; Reynisdottir et al. 1995; Aitman
et al. 1997; Vakkilainen et al. 1998). In FHCL, risk of
CHD is related to elevated TG (Austin et al. 2000).
Candidate-gene studies of FCHL have examined LPL
and the APOA1/C3/A4 (MIM 107680/107720/107690)
cluster, with conflicting results (Wojciechowski et al.
1991; Dallinga-Thie et al. 1996, 1997; Yang et al. 1996;
Pajukanta et al. 1997; Wijsman et al. 1998; Coon et al.
2000). Recently, TNFRSF1B, encoding tumor necrosis-
factor–receptor superfamily member 1B, was associated
with FCHL in Dutch subjects (Geurts et al. 2000), but
this could not be replicated in two independent Canadian
samples (author’s unpublished data).
More promising are the results of recent linkage stud-
ies, at least three of which, performed in independent
FCHL samples, provide evidence of a locus on chro-
mosome 1q21-q23 (Pajukanta et al. 1998; Coon et al.
2000; Pei et al. 2000). This region is syntenic to mouse
chromosome 3, which harbors a murine combined-hy-
perlipidemia gene (Castellani et al. 1998). Other loci
linked to FCHL are shown in table 3, consistent with
suggestions that FCHL is genetically heterogeneous.
Disorders of Remnant Lipoproteins
Remnant lipoproteins, known collectively as “b-VLDL,”
have a density of !1.006 g/ml and migrate in the b po-
sition on agarose-gel electrophoresis (Fredrickson et al.
1967). Some VLDL remnants can also be considered to
be IDL. Remnant lipoproteins (fig. 1C) are normally
rapidly catabolized by apo E–mediated RME, to either
LDLR or the cell-surface heparan sulfate proteoglycans/
LDLR-related protein complex or to heparan sulfate
proteoglycans alone (Mahley 1988; Mahley et al. 1999).
Remnant lipoproteins are atherogenic (Havel 2000).
In HL deficiency, remnant lipoproteins accumulate
owing to mutant LIPC, in which they are a part of the
complex dyslipidemia (Hegele et al. 1993). However,
the archetypal disorder of IDL excess is dysbetalipo-
proteinemia (Fredrickson type III) (MIM 107741)
(Mahley et al. 1999). Patients with this disorder typi-
cally have both elevated cholesterol and elevated TG,
to approximately equal concentrations (∼7.5 mmol/li-
ter, or ∼300 mg/dl), an elevated CE:TG ratio in VLDL,
characteristic skin findings (tuberous and/or palmar
xanthomas), and early atherosclerosis. The prevalence
of dysbetalipoproteinemia is ∼1:10,000 (Walden and
Hegele 1994). The molecular basis is the homozygosity
for the APOE E2 isoform, which differs from the com-
mon E3 isoform by a single amino acid substitution
(R158C) (Walden and Hegele 1994). Because ∼1% of
white individuals are E2/E2 homozygotes, secondary
environmental, metabolic, or genetic factors are re-
quired for disease expression. Other rare APOE mu-
tations produce this phenotype (Walden and Hegele
1994), but these are associated with AD inheritance and
with variable clinical severity due to differences in cell-
surface binding (Mahley et al. 1999).
Lipoprotein(a) (Lp[a])
Lp(a) has mesmerized researchers for 40 years (Berg
1992), but its biochemical and functional complexity
have thwarted delineation of its role in atherosclerosis
(Scanu and Fless 1990). Lp(a) (not shown in fig. 1) is
composed of LDL, with a single molecule of apo B-100
linked to the characteristic polymorphic protein apo(a)
(Scanu and Fless 1990). The structural similarity be-
tween apo(a) and plasminogen, together with the LDL
moiety, suggest a prothrombotic or atherogenic role, or
both (Marcovina et al. 1999; Scanu et al. 2001). Ret-
rospective case-control studies (Rhoads et al. 1986; Jau-
hiainen et al. 1991; Sorrentino et al. 1992) and popu-
lation-based prospective studies (Danesh et al. 2000)
have shown a strong association between Lp(a) and
CHD, although a direct causal role is uncertain (Mor-
risett 2000; Marcovina et al. 1999). Although there are
no reported monogenic syndromes of Lp(a) excess, size
polymorphism of the apo(a) gene on chromosome 6q26-
27 is responsible for ∼90% of the interindividual vari-
ation in plasma Lp(a) concentration (Boerwinkle et al.
1992; Cohen et al. 1993). Other genes might have minor
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Table 3
Results of Recent Selected Linkage Analyses from Genomewide Screening for Monogenic Dyslipidemias and Other
Plasma Lipoprotein Variation
Trait and Locus
LOD Score
or MLS Score Reference Comments
Cholesterol:
Total:
19p 3.89 Imperatore et al. (2000) Pima Indians
LDL:
1p32 6.8 Hunt et al. (2000) AD FH locus in a Utah family
3 (244 cM) 4.11 Rainwater et al. (1999) Quantitative-trait locus for LDL particle size
3p21.1-22 3.35 Yuan et al. (2000) AD FH locus
4 (126 cM) 4.11 Rainwater et al. (1999) Quantitative-trait locus for LDL particle size
13q 4.8 Knoblauch et al. (2000) LDL lowering in AD FH and normal relatives
HDL:
8 (150 cM) 4.87 Almasy et al. (1999) HDL composition
11q23 3.50 Kort et al. (2000) Familial hypoalphalipoproteinemia
15 (62 cM) 3.26 Almasy et al. (1999) HDL concentration and composition
Triglycerides:
15q 3.88 Duggirala et al. (2000) ∼40% of TG variation in Mexican Americans
apo AI:
12 (128 cM) 2.13 Klos et al. (2001) Families in Rochester, MN
apo AII:
4 (22 cM) 2.35 Klos et al. (2001) Families in Rochester, MN
5 (79 cM) 2.13 Klos et al. (2001) Families in Rochester, MN
TC:HDL ratio:
17 (125 cM) 2.48 Klos et al. (2001) Families in Rochester, MN
TG:HDL ratio:
7q32.3-qter 2.50 Shearman et al. (2000) Framingham offspring, nonstandard phenotype
FCHL:
1q21-23 5.93 Pajukanta et al. (1998) Finnish families with FCHL, primary locus
1q21-23 3.05 Coon et al. (2000) Independent replication, possible second locus
1q21-23 2.60 Pei et al. (2000) Replicated in Chinese and German families
10p11.2 3.20 Pajukanta et al. (1999) Finnish families with FCHL, high-TG subphenotype
11 (62 cM) 2.60 Aouizerat et al. (1999) Dutch families with FCHL, two-stage study design
21q21 2.24 Pajukanta et al. (1999) Finnish families with FCHL, high–apo B subphenotype
effects on plasma Lp(a) concentration (Hegele et al.
1997).
Sitosterolemia
Plant sterols consumed by humans are not utilized, and
their absorption from the intestine is selectively im-
peded: !5% of dietary plant sterols are absorbed, com-
pared to ∼50% of dietary cholesterol (Jones 1999).
Selective absorption of animal sterols over plant sterols
is defective in sitosterolemia, a rare AR disease (Lee et
al. 2001b). Patients with sitosterolemia accumulate
plant sterols in many tissues, have elevated plasma cho-
lesterol, and often develop early CHD. Patel et al.
(1998) mapped the sitosterolemia locus to 2p21 and
then used a genetic-mapping approach to identify the
causative genes, called “ABCG5” (MIM 605459) and
“ABCG8” (MIM 605460) (Lee et al. 2001a). Others
used genetic mapping and expression profiling to iden-
tify the sitosterolemia genes (Berge et al. 2000). These
tandemly arranged ABC-family members probably syn-
ergistically re-excrete absorbed cholesterol and sitos-
terol from enterocytes into the gut lumen (fig. 1B) and
from hepatocytes into bile (Berge et al. 2000; Lee et
al. 2001b; Lu et al. 2001). Cholesterol absorption is
probably increased in sitosterolemia. Two defective al-
leles for either ABCG5 or ABCG8, not just one defec-
tive allele for each, are required for sitosterolemia, sug-
gesting that these transporters function as heterodimers
(Lu et al. 2001).
Other Candidate Genes and Pathways for Plasma
Lipoproteins
No dyslipoproteinemia mutations have been detected in
most of the candidate-gene products that are directly
involved in lipoprotein assembly, secretion, transport,
processing, and catabolism. However, these genes are
interesting functional candidates for lipoprotein phe-
notypes. Other indirectly associated pathways, such as
BA synthesis, sterol synthesis, and fatty acid (FA) me-
tabolism, might affect lipoproteins, although it can be
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difficult to predict the phenotypic impact of a mutation
in a specific candidate gene.
Apolipoproteins and Receptors
No monogenic lipoprotein disorder has been shown to
be due to mutant apolipoproteins AII, AIV, CI, CIII, D,
H, or J. Very recently, a new apolipoprotein, called “apo
AV,” has been described, which appears to be important
in TGmetabolism, although no mutations causingmono-
genic hypertriglyceridemia were found (Pennacchio et al.
2001). Similarly, no monogenic dyslipidemia mutations
have been found in the LDLR-related protein LRP1 (MIM
107770). The VLDL receptor (VLDLR) (MIM 192977)
was hypothesized to mediate FA entry into peripheral tis-
sues, and it might have a role in TG metabolism (Tacken
et al. 2001). One very rare VLDLR mutation was found
in a subject with FCHL (Near et al. 2001). Scavenger-
receptor class B type 1 (SRB1, or CLA1) (MIM 601040)
is found in caveoli and promotes uptake of CE fromHDL
(fig. 1A) (Acton et al. 1996); however, no mutations have
yet been found in SRB1. Genes for other cell-surface re-
ceptors are interesting candidates for lipoproteins (Nich-
olson et al. 2000; van Berkel et al. 2000).
Lipases and Processing Proteins
No disease mutation has been found in endothelial
lipase (LIPG) (MIM 603684), which shares some se-
quence and functional similarity with other lipases (Jaye
et al. 1999). PNLIP hydrolyzes dietary TG (fig. 1B), and
deficiency causes fat malabsorption, failure to thrive,
and low plasma lipid levels; however, no mutations were
found in individuals who were PNLIP deficient (Hegele
et al. 2001), suggesting that other genes are defective.
PLTP is another interesting protein (Jiang et al. 1999),
with no reported mutations.
BA Metabolism
BA metabolism is currently a very topical area. In
addition to its role in cholesterol and dietary-fat ab-
sorption, bile is the preferred route of excretion formany
drugs and xenobiotics (Stieger and Meier 1998). BA ac-
tivates farnesyl X receptor (FXR), an orphan nuclear-
hormone receptor that mediates BA-dependent repres-
sion of CYP7A1, the initial and rate-limiting step in BA
synthesis (fig. 1A) (Russell and Setchell 1992; Repa and
Mangelsdorf 2000). FXR also regulates expression of
other proteins in BAmetabolism (Makishima et al. 1999;
del Castillo-Olivares and Gil 2000). Studies with recep-
tor-selective agonists have revealed that oxysterol recep-
tors and FXR are retinoid X receptor (RXR) heterodimer
partners that exert complementary effects on regulation
of expression of ABCA1 and CYP7A1 (Repa et al.
2000). The RXRA (MIM 180245) product is integrated
into diverse physiologic pathways, such as sterol, FA,
BA, and xenobiotic metabolism (Wan et al. 2000); how-
ever, no mutations have been found in RXRA (Hegele
and Cao 2001). Truncated CYP7A1 has been found in
an infant with cholestasis, cirrhosis, and elevated plasma
27-hydroxycholesterol (Setchell et al. 1998). Previously
mentioned mutations in SLC10A2 have been found to
be associated with low plasma LDL (Oelkers et al.
1997), underscoring the relationship with BA transport.
Mutant CYP27A1 encoding sterol 7-hydroxylase causes
cerebrotendinous xanthomatosis (MIM 213700), which
is characterized by tissue lipid deposits but normal
plasma lipoproteins (Cali et al. 1991).
Cholesterol Biosynthesis
The cholesterol biosynthetic pathway involves numer-
ous enzymes and bioactive intermediates (Goldstein and
Brown 1990). Multisystemic, mainly pediatric, disorders
are due to defects in cholesterol biosynthesis (Kelley
2000). Developmental abnormalities, elevated serum 7-
dehydrocholesterol, and low plasma cholesterol (Opitz et
al. 1994) define the most common of these disorders—
namely, Smith-Lemli-Optiz syndrome (SLOS) (MIM
270400). SLOS is caused by mutations in sterol delta-7-
reductase (DHCR7) (MIM 602858) (Wassif et al. 1998;
Waterham et al. 1998). Risk of CHD is moot, because of
other systemic abnormalities, and dietary-cholesterol sup-
plements might improve cognitive development (Kelley
1998; Nowaczyk et al. 2001). There are no reported mu-
tations in either 3-hydroxy-3-methylglutaryl (HMG)-CoA
reductase (HMGCR) (MIM 142910), which catalyzes the
committed synthetic step, or cytoplasmic HMGCoA syn-
thase (HMGCS1) (MIM 142940), which mediates an
early synthetic step. However, mutant mitochondrial
HMGCoA synthase (HMGCS2) (MIM 600234), the first
enzyme in ketogenesis, is associated with abnormal me-
tabolism of glucose and FA but with normal plasma lipo-
proteins (Bouchard et al. 2001).
Cholesterol Esterification
An essential intracellular element in the formation of
CE from cholesterol is ACAT—although the preferred
MIM symbol is “SOAT,” since “ACAT” has previously
been given to a different enzyme with ketothiolase ac-
tivity (see MIM 203750). SOAT1 (MIM 102642) and
SOAT2 (MIM 601311) are members of a transferase
family (Chang et al. 1993, 2001 Anderson et al. 1998;
Cases et al. 1998a, 1998b; Oelkers et al. 1998). SOAT
products (fig. 1A, B, and D) generate CE for storage as
lipid droplets, play a role in foam-cell formation, are
involved in dietary-cholesterol absorption, and supply
CE for lipoprotein synthesis. Approximately 80% of
newly absorbed cholesterol transported within CM en-
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ters the body as CE esterified by SOAT. Although there
are no SOAT mutations, the genes’ importance has been
shown by abnormal phenotypes in murine models (Mei-
ner et al. 1996; Buhman et al. 2000).
TG Synthesis
Acyl-CoA:diacylglycerol acyltransferase (DGAT) is a
microsomal enzyme that catalyzes the terminal and only
committed step in TG synthesis. DGAT had been con-
sidered to be both necessary for adipose-tissue formation
and essential for survival. Two groups (Cases et al.
1998a; Oelkers et al. 1998) have independently cloned
DGAT (MIM 604900). Although there are no human
DGAT mutations, targeted disruption produces lean
mice that resist diet-induced obesity but that still syn-
thesize TG (Smith et al. 2000), suggesting the existence
of other DGAT-like enzymes.
FA Uptake and Synthesis
Several different classes of membrane proteins have
been proposed as FA acceptors or transporters (Glatz
and Storch 2001). FA trafficking by soluble intracellular
FA-binding proteins may involve interaction with spe-
cific membrane or protein targets. No dyslipidemia re-
sults from mutations in these genes, but Bietti crystalline
corneoretinal dystrophy (MIM 210370) may be due to
mutations in FA-binding proteins (Jiao et al. 2000). Dis-
eases due to mutant-FA synthetic enzymes do not feature
altered plasma lipoproteins (Treem et al. 1991).
Other Regulators of Cellular Lipid Homeostasis
FA synthesis is regulated by various transcription fac-
tors, such as membrane-bound sterol regulatory ele-
ment–binding protein-1 (SREBP1) (MIM 184756). Reg-
ulators of SREBP-1 include polyunsaturated FA, glucose,
and insulin (Sakai and Rawson 2001). Accumulation of
intracellular cholesterol suppresses the proteolytic re-
lease of the active N-terminal fragment of SREBP from
the membrane-bound precursor (Sakai and Rawson
2001). Induced SREBP mutations in mice produce im-
portant metabolic phenotypes, such as lipodystrophy
and insulin resistance (Shimomura et al. 1999). How-
ever, no human mutations have yet been reported, in
either the genes for SREBPs, their processing enzymes,
or interacting cofactors.
Monogenic Determinants of Metabolic Conditions
with Secondary Dyslipidemia
Common dyslipidemia is associated with such metabolic
traits as obesity and diabetes (National Cholesterol Ed-
ucation Program 2001). However, dyslipidemia in
monogenic forms of obesity and diabetes has not been
systematically examined. This issue was addressed inCa-
nadian kindreds with familial partial lipodystrophy of
the Dunnigan type (FPLD) (MIM 151660), an AD form
of insulin-resistant diabetes due to mutantLMNA (MIM
150330) encoding nuclear lamin A/C (Cao and Hegele
2000). The initial metabolic abnormality in FPLD is hy-
perinsulinemia due to insulin resistance, followed by
dyslipidemia—that is, elevated TG and low HDL (He-
gele et al. 2000a)—followed by diabetes and then pre-
mature CHD (Hegele 2001). Dyslipidemia in FPLD is
thus secondary to monogenic insulin resistance. Another
relatively large group that was studied are the Oji-Cree
of Ontario, whose very high prevalence of type 2 dia-
betes was largely explained by the private G319S mu-
tation in HNF1A (MIM 142410) encoding factor he-
patic nuclear factor-1a (Hegele et al. 1999). The
development of diabetes in the Oji-Cree was associated
with worsened plasma lipoproteins—that is, increases
both in total and LDL cholesterol and in TG, with a
decrease in HDL cholesterol—but theHNF1Amutation
also had an independent association with plasma lipo-
proteins (Hegele et al. 2000b).
Additional Loci Revealed by Genomewide Scans and
Linkage Analysis
As suggested above in the “Monogenic Disorders with
LDL Excess” subsection, additional heterogeneity is very
likely for monogenic dyslipidemias, such as AD FH
(Hunt et al. 2000), AD hypobetalipoproteinemia (Knob-
lauch et al. 2000), AD hypoalphalipoproteinemia (Kort
et al. 2000), and FCHL. Loci identified by genomewide
scanning, with either the LOD score or the maximum
LOD score, are shown in table 3.
Common Genetic Polymorphisms, Plasma
Lipoproteins, and CHD
Association studies using common single-nucleotide
polymorphisms (SNPs) and insertion/deletion variants
are a mainstay of lipoprotein research: a recent Medline
search using the terms “human,” “lipids,” and “poly-
morphisms” identified ∼1,600 original articles dating
from 1982. From a clinical perspective, only the APOE
isoforms are useful for diagnosis and treatment strati-
fication (Walden and Hegele 1994). There is fairly con-
sistent evidence that E4 is associated with higher plasma
LDL cholesterol and, also, with worsened noninvasive
measurements of atherosclerosis (Smith 2000). APOE
genotyping can reveal subjects with E2/E2 who are at
increased risk of dysbetalipoproteinemia and also can
fortuitously reveal rare APOEmutations (Hegele 1999).
Nontraditional risk factors for CHD, such as APOE
genotype, may help to reassign patients to higher-risk
strata than those predicted by traditional risk factors.
Other functional SNPs that might become clinically use-
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ful include those within LPL (Talmud and Humphries
2001), LIPC (Cohen et al. 1999), and APOC3 (Shachter
2001).
Conclusions
Early candidate-gene studies and recent positional-clon-
ing experiments have revealed pathways underlying the
monogenic disorders of lipoprotein metabolism. Genetic
heterogeneity for monogenic dyslipidemias suggests that
newer molecules and pathways remain to be discovered.
Elucidating these pathways may provide new targets for
novel intervention strategies. For patients who are not
part of a kindred with a defined monogenic dyslipide-
mia, the clinical value of molecular diagnosis is unclear;
for instance, 1600 LDLR mutations underlie AD FH,
but no single LDLR SNP has been associated with var-
iation of plasma lipoproteins in the general population.
Other than APOE isoforms, it is not clear, at present,
whether any common genetic variant will help to predict
risk of CHD in the general population, beyond estimates
derived from clinical and biochemical determinations.
Finally, the influence that single genes have on dyslipide-
mia is modulated by interactions with genetic back-
ground and/or secondary genetic effects, in addition to
gender, age, hormone replacement, and diet. These mod-
ulating factors are likely to be even more important for
the common polygenic dyslipidemias.
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